Literature DB >> 11023189

Borreliacidal activity of early Lyme disease sera against complement-resistant Borrelia afzelii FEM1 wild-type and an OspC-lacking FEM1 variant.

Peter Kraiczy, Klaus-Peter Hunfeld, Stefan Peters, Reinhard Würzner1, Georg Acker1, Bettina Wilske1, Volker Brade.   

Abstract

Sera obtained from 14 Lyme borreliosis patients at early stages (stages I and II) of the disease were examined for their borreliacidal properties against Borrelia afzelii isolate FEM1 by use of a growth inhibition assay. Five of 14 immune sera exhibited borreliacidal activity against isolate FEM1. Heat-inactivated immune sera failed to kill the spirochaetes. Immunoblotting experiments with outer-membrane preparations showed that OspC and 11 additional proteins of 14.0, 16.0, 17.7, 19.3, 21.7, 27.5, 32.7, 40.7, 48.9, 51.3 and 53.6 kDa were recognised by borreliacidal immune sera. To analyse the borreliacidal properties of anti-OspC antibodies, two sera (EM4 and EM5), which beside antibodies against a 51.3-kDa protein contained exclusively anti-OspC antibodies, were further investigated by comparative analysis with a FEM1 wild-type and a FEM1 variant lacking OspC in a growth inhibition assay. Only FEM1 wild-type and not variant FEM1OspC(-) was killed by immune sera EM4 and EM5. Complement-dependent killing of FEM1 wild-type was mediated by formation of the terminal complement complex that was found to be attached directly to the outer membrane as confirmed by immuno-electron microscopy. No complement deposition was observed on the surface of variant FEM1OspC(-) after incubation with immune sera EM4 and EM5, thereby suggesting that only anti-OspC antibodies in these two immune sera were responsible for borreliacidal activity. These results provide direct evidence that anti-OspC antibodies, once developed during the immune response, are of critical importance for efficient killing of borreliae in the early phase of infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11023189     DOI: 10.1099/0022-1317-49-10-917

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  10 in total

1.  In vitro assessment of antiborrelial activity of OspA vaccine sera.

Authors:  Paul T Fawcett; Carlos D Rose; Kathleen M Gibney
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  Blood treatment of Lyme borreliae demonstrates the mechanism of CspZ-mediated complement evasion to promote systemic infection in vertebrate hosts.

Authors:  Ashley L Marcinkiewicz; Alan P Dupuis; Maxime Zamba-Campero; Nancy Nowak; Peter Kraiczy; Sanjay Ram; Laura D Kramer; Yi-Pin Lin
Journal:  Cell Microbiol       Date:  2019-01-07       Impact factor: 3.715

3.  Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes.

Authors:  Brian Stevenson; Nazira El-Hage; Melissa A Hines; Jennifer C Miller; Kelly Babb
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Borreliacidal OspC antibodies specific for a highly conserved epitope are immunodominant in human lyme disease and do not occur in mice or hamsters.

Authors:  Steven D Lovrich; Dean A Jobe; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

5.  Inadequate binding of immune regulator factor H is associated with sensitivity of Borrelia lusitaniae to human complement.

Authors:  Roswitha Dieterich; Claudia Hammerschmidt; Dania Richter; Christine Skerka; Reinhard Wallich; Franz-Rainer Matuschka; Peter F Zipfel; Peter Kraiczy
Journal:  Infect Immun       Date:  2010-09-07       Impact factor: 3.441

6.  Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi.

Authors:  P Kraiczy; C Skerka; V Brade; P F Zipfel
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

7.  C-terminal region of outer surface protein C binds borreliacidal antibodies in sera from patients with Lyme disease.

Authors:  Dean A Jobe; Steven D Lovrich; Ronald F Schell; Steven M Callister
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

8.  Ability of the borreliacidal antibody test to confirm lyme disease in clinical practice.

Authors:  Steven M Callister; Dean A Jobe; William A Agger; Ronald F Schell; Todd J Kowalski; Steven D Lovrich; Jennifer A Marks
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

9.  Borreliacidal OspC antibody response of canines with Lyme disease differs significantly from that of humans with Lyme disease.

Authors:  Steven D Lovrich; Rhonda L La Fleur; Dean A Jobe; Jennifer C Johnson; Krista E Asp; Ronald F Schell; Steven M Callister
Journal:  Clin Vaccine Immunol       Date:  2007-03-07

10.  Inferring epitopes of a polymorphic antigen amidst broadly cross-reactive antibodies using protein microarrays: a study of OspC proteins of Borrelia burgdorferi.

Authors:  Elisabeth Baum; Arlo Z Randall; Michael Zeller; Alan G Barbour
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.